|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Association between autoimmune pancreatitis and systemic autoimmune diseases显示文摘AIM: To investigate the association between autoimmune pancreatitis (AIP) and systemic autoimmune diseases (SAIDs) by measurement of serum immunoglobulin G4 (IgG4). METHODS: The serum level of IgG4 was measured in 61 patients with SAIDs of different types who had not yet participated in glucocorticosteroid treatment. Patients with an elevated IgG4 level were examined by abdominal ultrasonography (US) and, in some cases, by computer tomography (CT). RESULTS: Elevated serum IgG4 levels (919 ± 996 mg/L) were detected in 17 (28%) of the 61 SAID patients. 10 patients had Sj gren's syndrome (SS) (IgG4: 590 ± 232 mg/L), 2 of them in association with Hashimoto's thyroiditis, and 7 patients (IgG4: 1388 ± 985.5 mg/L) had systemic lupus erythematosus (SLE). The IgG4 level in the SLE patients and that in patients with SS were not significantly different from that in AIP patients (783 ± 522 mg/L). Abdominal US and CT did not reveal any characteristic features of AIP among the SAID patients with an elevated IgG4 level. CONCLUSION: The serum IgG4 level may be elevated in SAIDs without the presence of AIP. The determination of serum IgG4 does not seem to be suitable for the differentiation between IgG4-related diseases and SAIDs. | Viktória Terzin Imre Fldesi László Kovács Gyula Pokorny Tibor Wittmann László Czakó | 2012 | World Journal of Gastroenterology2012，18，21： | 9 |
| 2 | Residual renal function in peritoneal dialysis with failed allograft and minimum immunosuppression显示文摘Immunosuppression(IS) is often withdrawn in patients with end stage renal disease secondary to a failed renal allograft, and this can lead to an accelerated loss of residual renal function(RRF). As maintenance of RRF appears to provide a survival benefit to peritoneal dialysis(PD) patients, it is not clear whether this benefit of maintaining RRF in failed allograft patients returning to PD outweigh the risks of maintaining IS. A 49 year-old Caucasian male developed progressive allograft failure nine years after living-donor renal transplantation. Hemodialysis was initiated via tunneled dialysis catheter(TDC) and IS was gradually withdrawn. Two weeksafter IS withdrawal he developed a febrile illness, which necessitate removal of the TDC and conversion to PD. He was maintained on small dose of tacrolimus(1 mg/d) and prednisone(5 mg/d). Currently(1 year later) he is doing exceedingly well on cycler-assisted PD. Residual urine output ranges between 600-1200 m L/d. Total weekly Kt/V achieved 1.82. RRF remained well preserved in this patient with failed renal allograft with minimal immunosuppressive therapy. This strategy will need further study in well-defined cohorts of PD patients with failed allografts and residual RRF to determine efficacy and safety. | Nadear Elmahi éva Csongrádi Kenneth Kokko Jack R Lewin Jamie Davison Tibor Fülp | 2013 | World Journal of Transplantation2013，3，2： | 5 |
| 3 | Biological therapy in inflammatory bowel diseases:Access in Central and Eastern Europe显示文摘Biological drugs opened up new horizons in the management of inflammatory bowel diseases(IBD).This study focuses on access to biological therapy in IBD patients across 9 selected Central and Eastern European(CEE)countries,namely Bulgaria,the Czech Republic,Estonia,Hungary,Latvia,Lithuania,Poland,Romania and Slovakia.Literature data on the epidemiology and disease burden of IBD in CEE countries was systematically reviewed.Moreover,we provide an estimation on prevalence of IBD as well as biological treatment rates.In all countries with the exception of Romania,lower biological treatment rates were observed in ulcerative colitis(UC)compared to Crohn’s disease despite the higher prevalence of UC.Great heterogeneity(up to 96-fold)was found in access to biologicals across the CEE countries.Poland,Bulgaria,Romania and the Baltic States are lagging behind Hungary,Slovakia and the Czech Republic in their access to biologicals.Variations of reimbursement policy may be one of the factors explaining the differences to a certain extent in Bulgaria,Latvia,Lithuania,and Poland,but association with other possible determinants(differences in prevalence and incidence,price of biologicals,total expenditure on health,geographical access,and cost-effectiveness results)was not proven.We assume,nevertheless,that healthdeterioration linked to IBD might be valued differently against other systemic inflammatory conditions in distinct countries and which may contribute to the immense diversity in the utilization of biological drugs for IBD.In conclusion,access to biologicals varies widely among CEE countries and this difference cannot be explained by epidemiological factors,drug prices or total health expenditure.Changes in reimbursement policy could contribute to better access to biologicals in some countries. | Fanni Rencz Márta Péntek Martin Bortlik Edyta Zagorowicz Tibor Hlavaty Andrzej Sliwczyński Mihai M Diculescu Limas Kupcinskas Krisztina B Gecse László Gulácsi Peter L Lakatos | 2015 | World Journal of Gastroenterology2015，21，6： | 4 |
| 4 | Minimization vs tailoring:Where do we stand with personalized immunosuppression during renal transplantation in 2015?显示文摘The introduction of novel immunosuppressive agents over the last two decades and the improvement of our diagnostic tools for early detection of antibodymediated injury offer us an opportunity, if not a mandate, to better match the immunosuppression needs of the individual patients with side effects of the therapy. However, immunosuppressive regimens in the majority of programs remain mostly protocol-driven, with relatively little inter-program heterogeneity in certain areas of the world. Emerging data showing different outcomes with a particular immunosuppressive strategy in populations with varying immunological risks underscore a real potential for 'personalized medicine' in renal transplantation. Studies demonstrating marked differences in the adverse-effect profiles of individual drugs including the risk for viral infections, malignancy and renal toxicity call for a paradigm shift away from a 'one size fits all' approach to an individually tailored immunosuppressive therapy for renal transplant recipients, assisted by both screening for predictors of graft loss and paying close attention to dose or class-related adverse effects. Our paper explores some of the opportunities during the care of these patients. Potential areas of improvements may include:(1) a thorough assessment of immunological and metabolic risk profile of each renal transplant recipient;(2) screening for predictors of graft loss and early signs of antibody-mediated rejection with donor-specific antibodies, protocol biopsies and proteinuria(including close follow up of adverse effects with dose adjustments or conversions as necessary); and(3) increased awareness of the possible link between poor tolerance of a given drug at a given dose and non-adherence with the prescribed regimen. Altogether, these considerations may enable the most effective use of the drugs we already have. | Lajos Zsom László Wagner Tibor Fül?p | 2015 | World Journal of Transplantation2015，5，3： | 3 |
| 5 | Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy显示文摘AIM:To assess the endoscopic activity before and after a one-year period of biological therapy and to evaluate the frequency of relapses and need for retreatment after stopping the biologicals in patients with Crohn’s disease(CD)and ulcerative colitis(UC).METHODS:The data from 41 patients with CD and 22 patients with UC were assessed.Twenty-four CD patients received infliximab,and 17 received adalimumab.The endoscopic severity of CD was quantified with the simplified endoscopic activity score for Crohn’s disease in CD and with the Mayo endoscopic subscore in UC.RESULTS:Mucosal healing was achieved in 23 CD and7 UC patients.Biological therapy had to be restarted in78%of patients achieving complete mucosal healing with CD and in 100%of patients with UC.Neither clinical remission nor mucosal healing was associated with the time to restarting the biological therapy in either CD or UC.CONCLUSION:Mucosal healing did not predict sustained clinical remission in patients in whom the biological therapies had been stopped. | Klaudia Farkas Péter László Lakatos Mónika Szcs va Pallagi-Kunstár Anita Bálint Ferenc Nagy Zoltán Szepes Noémi Vass Lajos S Kiss Tibor Wittmann Tamás Molnár | 2014 | World Journal of Gastroenterology2014，20，11： | 2 |
| 6 | The hyperbolic tangent distribution family 显示文摘 | TIBOR B BELA L CSABA M | 1998 | Powder Technology1998，97，： | 2 |
| 7 | Protection of Balb/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant显示文摘 | Mariri A L Tibor A Mertens P | 2001 | Infect Immun2001，69，： | 1 |
| 8 | Polymer recycling:potential application of radiation technology显示文摘 | Guillermina Burilloa Roger L Cloughb Tibor Czvikovszkyc | 2002 | Radiation Physics and Chemistry2002，64，1： | 1 |
| 9 | Design of potent, non-toxic antimicrobial agents based upon the structure of the frog skin peptide, pseudin-2显示文摘 | Tibor Pál ágnes Sonnevend Sehamuddin Galadari J. Michael Conlon | 2005 | Regulatory Peptides2005，，1： | 1 |
| 10 | External field coupling to MTL net works with nonlinear junctions:numerical modeling and experimental validation显示文摘 | Joe L Joe S | 2000 | IEEE Transactions on Electromagnetic Compatibility2000，42，1： | 1 |
| 11 | HLA-DRI is associated with vitiligo显示文摘 | Poloy A Tibor L Kramer J | 1991 | Immunol Lett1991，27，： | 1 |
| 12 | Management of medial-sided knee injuries,part 2:posteromedial corner显示文摘 | Tibor L M Marchant M H Jr Taylor D C | 2011 | Am J Sports Med2011，39，6： | 1 |
| 13 | Impact of Positive Intraabdominal Lavage Cytology on the Long-term Prognosis of Colorectal Cancer Patients显示文摘 | Rita Temesi László Sikorszki János Bezsilla ákos Botos Judit Kovács Tibor Tihanyi | 2012 | World Journal of Surgery2012，，11： | 1 |
| 14 | Impaired Endothelial Repair Capacity of Early Endothelial Progenitor Cells in Prehypertension: Relation to Endothelial Dysfunction显示文摘 | Giovanna Giannotti Carola Doerries Pavani S. Mocharla Maja F. Mueller Ferdinand H. Bahlmann Tibor Horvàth Hong Jiang Sajoscha A. Sorrentino Nora Steenken Costantina Manes Mario Marzilli K. Lenhard Rudolph Thomas F. Lüscher Helmut Drexler Ulf Landmesser | 2010 | Hypertension2010，，6： | 1 |
| 15 | Biomechanical properties of normal and fibrosclerotic human cerebral arteries显示文摘 | Hudetz AG Gyrgy Márk Kovách AGB Tibor Kerényi László Fody Emil Monos | 1981 | Atherosclerosis1981，39，3： | 1 |
| 16 | FINGER, Refinement of the hematite structure显示文摘 | Blake R L Hessevick R E Tibor Z | 1966 | American Mineralogist1966，51，1： | 1 |
| 17 | Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice显示文摘 | Tibor A Jaques I Guilloteau L | 1998 | Infect Immun1998，66，： | 1 |
| 18 | Clinical outcomes after ante- rior cruciate ligament reconstruction: a meta - analysis of autograft versus allograft tissue显示文摘 | Tibor L M Long J L Schilling P L | 2010 | Sports Health2010，2，1： | 1 |
| 19 | Factors contributing to enhanced freezing tolerance in wheat during frost hardening in the light 显示文摘 | TIBOR J GABRIELLA S KORNELIA L | 2007 | Phytochemistry2007，12，： | 1 |
| 20 | Effect of P39 gene deletion in live Brucella vaccine strains on residual virulence and protective activity in mice显示文摘 | Tibor A Jaques I Guilloteau L | 1998 | Infect Immun1998，，66： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员